Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_3
1
11%
Ph phase_4
3
33%
Ph phase_1
1
11%
Ph phase_2
2
22%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Not yet recruiting2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 31 (14.3%)
Phase 43 (42.9%)

Trials by Status

terminated111%
withdrawn111%
not_yet_recruiting222%
completed556%

Recent Activity

0 active trials
Showing 5 of 9
not_yet_recruitingphase_2

Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin

NCT07225465
not_yet_recruitingphase_2

Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy

NCT07096986
completedphase_4

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

NCT05743907
withdrawnphase_3

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

NCT03766750
completedphase_1

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

NCT04473417
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07225465Phase 2

Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin

Not Yet Recruiting
NCT07096986Phase 2

Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy

Not Yet Recruiting
NCT05743907Phase 4

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

Completed
NCT03766750Phase 3

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Withdrawn
NCT04473417Phase 1

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

Completed
NCT04193566Phase 4

Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes

Completed
NCT02561130Phase 4

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

Completed
NCT03407196

Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey

Completed
NCT01944618

forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9